Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NC18
- Development stage
- Unknown
- Lead developer
- Novacyte Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NC18 is a novel HER2-targeting antibody-drug conjugate (ADC) developed by Novacyte Therapeutics. It consists of a humanized monoclonal antibody directed against HER2, conjugated via a PHF (poly-1-hydroxymethylethylene hydroxymethyl-formal) polymer linker to AF-HEA, a tubulin-inhibiting payload that is an analog of Auristatin F (MMAF). NC18 is designed to treat HER2-expressing advanced solid tumors, including breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma. Preclinical data indicates that NC18 maintains anti-tumor activity in tumor models resistant to trastuzumab deruxtecan (Enhertu), suggesting it may provide a therapeutic option for patients who have developed resistance to existing HER2-targeted ADCs. The drug is currently in Phase 1 clinical development.
- Other names
- NC18NC-18NC 18
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on NC18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NC18.